Why Covid-19 vaccines face a new obstacle course

From a shortage of dry ice to Brexit traffic jams, hurdles still threaten our ability to inoculate the world

Amid all the good news on Covid vaccine, many obstacles remains to its successful rollout

Amid all the good news on Covid vaccine, many obstacles remains to its successful rollout

 

The race to find an effective vaccine appears to be on the home straight. The same cannot be said of the race to roll it out everywhere. Preparing to present a BBC radio series titled How to Vaccinate the World, I’ve been looking at the route ahead. It is less of a marathon, more of an assault course.

So, in no particular order, here is a brief guide to some of the obstacles that remain.

- Efficacy (1). Do these vaccines – of which there are more than a hundred in prospect and about a dozen in last-stage development – actually work? The recent announcements that the Pfizer/BioNTech vaccine appears to be 95 per cent effective and the Moderna one almost the same are very encouraging and bode well for other vaccines. The good news from Pfizer may be even better than it appears – reading between the lines, some statisticians speculate that the efficacy is closer to 97 per cent.

But the fact that every nerd in the world is trying to reverse-engineer the actual numbers behind Pfizer’s press release is cause for concern. It’s understandable that the announcement came by press release rather than a peer-reviewed paper; the news was just too big to be kept secret while drafts were circulated. But more data should have been released sooner.

- Production lines. A vaccine is one of the most complex products in the world to produce, and the process of scaling up from tens of thousands of doses for a trial to hundreds of millions for mass vaccination is not a trivial one.

- Efficacy (2). Will these vaccines make people less infectious or will they simply prevent severe illness? Either would be good, but preventing the spread of infection would be ideal. The Pfizer press release leaves us guessing for now. Since the Sars-Cov-2 virus accumulates in the upper respiratory tract before causing symptoms, there is a real risk that vaccines will not prevent people from spreading the virus even if they are largely immune to the disease.

- Missing links. Earlier in the pandemic, testing capacity was limited by the availability of suitable swabs. It’s often the simple stuff that trips us up. There were fears of a shortage of glass vials, but this was predicted and is being addressed. But now trade publication Gasworld reports an “acute” shortage of dry ice, thanks to increased demand for food preservation this year. That’s a problem, because dry ice is also useful for keeping vaccines cold.

- Logistics. In a major and under-appreciated miracle, more than 85 per cent of children are now fully vaccinated against diphtheria, tetanus and pertussis. Rates of vaccination for tuberculosis, polio, hepatitis B and measles are similarly impressive. So the cold chain needed to maintain many vaccines, which is the temperature of a beer fridge, is well established.

We even have cold chains developed to support the distribution of the polio vaccine, which needs to be kept at -20C, a temperature achievable by a domestic freezer. But the new Pfizer/BioNTech vaccine needs to be kept at -70C. This ultra-cold chain will not be trivial to maintain.

- Brexit. I don’t want to kill the mood but the advisers surrounding UK prime minister Boris Johnson have been fighting like rats in a barrel. They seem woefully underprepared for – or perhaps indifferent to – the prospect of a no-deal Brexit on New Year’s Day.

The chemicals industry is seriously worried that cross-border transfers of pharmaceutical drugs and other chemicals will be badly disrupted. If there is a fight to allocate syringes, vials or other hitherto overlooked components in the supply chain, I worry that we have made few friends in the past four years.

And even if there is nothing to worry about except a queue at the border, the Pfizer vaccine is going to be manufactured in Belgium and Germany and, remember, needs to be stored at a temperature of -70C. Calais can get cold in January but it doesn’t get that cold.

- Crowd control. It would be nice if each vaccine were stored in a single-dose pack. A patient could stroll up to a clinic and get vaccinated at a convenient moment. But the ultra-cold chain will rely on fancy “thermal shippers” storing a thousand doses or more; each glass vial will contain five or 10 doses. Break the seal on a big batch of vaccines and you’re going to want a large number of people coming through the door in short order. Getting socially distanced people in the right place at the right time for their shots, especially in rural areas, may not be easy.

- Paperwork. Most of the serious vaccine candidates require two doses. Not only do we have to figure out who is getting vaccinated when, but we need to get them back again for a second dose 21 days later. If this sounds like it shouldn’t be too much trouble for a modern healthcare system to handle, then I have an obsolete version of Microsoft Excel to sell you.

- Efficacy (3). How long does immunity last? Having to vaccinate the entire planet every six months would be quite a performance. Let’s hope the vaccine works for a longer period than that, but for obvious reasons it is far too early to tell.

- The Donald. Yes, him. Trump was prominent in spreading the false idea that vaccines cause autism, but last year changed his tune, urging people “to get the shots”. Would an embittered Trump, eager to spite his successor and win attention for his future media or political career, become a prominent anti-vaxxer again? To ask the question is to answer it.

Don’t be depressed about this far from exhaustive list. It is a miracle that, less than a year after the virus was sequenced, we seem to have two effective vaccines and many more on the way. I am excited and optimistic. But this story has a few twists in it yet. – Copyright The Financial Times Limited 2020

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
GO BACK
Error Image
The account details entered are not currently associated with an Irish Times subscription. Please subscribe to sign in to comment.
Comment Sign In

Forgot password?
The Irish Times Logo
Thank you
You should receive instructions for resetting your password. When you have reset your password, you can Sign In.
The Irish Times Logo
Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.
Screen Name Selection

Hello

Please choose a screen name. This name will appear beside any comments you post. Your screen name should follow the standards set out in our community standards.

The Irish Times Logo
Commenting on The Irish Times has changed. To comment you must now be an Irish Times subscriber.
SUBSCRIBE
Forgot Password
Please enter your email address so we can send you a link to reset your password.

Sign In

Your Comments
We reserve the right to remove any content at any time from this Community, including without limitation if it violates the Community Standards. We ask that you report content that you in good faith believe violates the above rules by clicking the Flag link next to the offending comment or by filling out this form. New comments are only accepted for 3 days from the date of publication.